
Sign up to save your podcasts
Or


Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content:
By JAMA Network4.4
472472 ratings
Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content:

321 Listeners

549 Listeners

701 Listeners

163 Listeners

260 Listeners

906 Listeners

3,374 Listeners

38 Listeners

21 Listeners

16 Listeners

11 Listeners

8 Listeners

17 Listeners

19 Listeners

5 Listeners

6 Listeners

1,150 Listeners

31 Listeners

9 Listeners

94 Listeners

141 Listeners

14 Listeners

5 Listeners

518 Listeners

5 Listeners

367 Listeners

260 Listeners

437 Listeners

106 Listeners

18 Listeners

320 Listeners

2 Listeners

325 Listeners

270 Listeners